CalciMedica Q1 net income $0.1M; CARPO Phase 2b enrollment completed; cash into 2H 2025

CalciMedica, Inc.

2024-Q1 EPS reported $0.01

Net income of $0.1M ($0.01/share) driven by $5.6M non-cash gain on warrant liability, offsetting $5.8M operating loss.
Cash & equivalents $25.7M as of March 31, 2024; expected to fund operations into second half of 2025.
Phase 2b CARPO trial (Auxora in acute pancreatitis) fully enrolled at 216 patients; topline data expected in Q2 2024.
Phase 2 KOURAGE trial (Auxora in severe AKI with respiratory failure) cleared by FDA; first patient enrollment expected Q2 2024.
Private placement raised up to ~$54M ($20.4M upfront, ~$33.1M warrants) to support ongoing and planned trials.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CalciMedica, Inc. reported the first quarter ended March 31, 2024 results: net income $0.1 million, EPS $0.01 per share (basic and diluted).

Period: the first quarter ended March 31, 2024
Net income: $0.1 million
EPS: $0.01 per share (basic and diluted)
Result: reported results

Exact text from the filing

With the impact of a $5.6 million non-cash gain from the fair value adjustment of the warrant liability, net income was $0.1 million, or $0.01 per share (basic and diluted) for the three months March 31, 2024.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

CalciMedica, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-058730

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.